SG10201408115SA - Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders - Google Patents

Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Info

Publication number
SG10201408115SA
SG10201408115SA SG10201408115SA SG10201408115SA SG10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA SG 10201408115S A SG10201408115S A SG 10201408115SA
Authority
SG
Singapore
Prior art keywords
tetrahydropyridines
disorders
treatment
related disease
sodium channel
Prior art date
Application number
SG10201408115SA
Other languages
English (en)
Inventor
Kumar Ratty Anil
Entzeroth Michael
Original Assignee
Chakra Biotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chakra Biotech Pte Ltd filed Critical Chakra Biotech Pte Ltd
Priority to SG10201408115SA priority Critical patent/SG10201408115SA/en
Priority to EP15864987.1A priority patent/EP3226865A4/en
Priority to PCT/SG2015/050461 priority patent/WO2016089304A1/en
Priority to AU2015355612A priority patent/AU2015355612B2/en
Priority to SG11201701618SA priority patent/SG11201701618SA/en
Priority to US15/522,510 priority patent/US10414728B2/en
Priority to JP2017530206A priority patent/JP6493711B2/ja
Publication of SG10201408115SA publication Critical patent/SG10201408115SA/en
Priority to US15/874,592 priority patent/US20180141907A1/en
Priority to JP2019006802A priority patent/JP2019070036A/ja
Priority to AU2019284008A priority patent/AU2019284008A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SG10201408115SA 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders SG10201408115SA (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SG10201408115SA SG10201408115SA (en) 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
EP15864987.1A EP3226865A4 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
PCT/SG2015/050461 WO2016089304A1 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
AU2015355612A AU2015355612B2 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
SG11201701618SA SG11201701618SA (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
US15/522,510 US10414728B2 (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
JP2017530206A JP6493711B2 (ja) 2014-12-05 2015-11-19 ナトリウムチャネル関連疾患及び障害の治療におけるテトラヒドロピリジンの使用
US15/874,592 US20180141907A1 (en) 2014-12-05 2018-01-18 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
JP2019006802A JP2019070036A (ja) 2014-12-05 2019-01-18 ナトリウムチャネル関連疾患及び障害の治療におけるテトラヒドロピリジンの使用
AU2019284008A AU2019284008A1 (en) 2014-12-05 2019-12-20 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201408115SA SG10201408115SA (en) 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Publications (1)

Publication Number Publication Date
SG10201408115SA true SG10201408115SA (en) 2016-07-28

Family

ID=56092099

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201408115SA SG10201408115SA (en) 2014-12-05 2014-12-05 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
SG11201701618SA SG11201701618SA (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701618SA SG11201701618SA (en) 2014-12-05 2015-11-19 Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders

Country Status (6)

Country Link
US (2) US10414728B2 (ja)
EP (1) EP3226865A4 (ja)
JP (2) JP6493711B2 (ja)
AU (2) AU2015355612B2 (ja)
SG (2) SG10201408115SA (ja)
WO (1) WO2016089304A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106431911B (zh) * 2016-09-28 2021-05-28 黄石市利福达医药化工有限公司 一种4-联苯乙酸的制备与纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410746B1 (en) * 1999-04-27 2002-06-25 Research Foundation Of State University Of New York, The Metal cataltsts and methods for making and using same
WO2006047330A2 (en) 2004-10-22 2006-05-04 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2006078984A2 (en) 2005-01-20 2006-07-27 Institute For Molecular Medicine, Inc. Uses of methylphenidate derivatives
US7700798B1 (en) * 2005-06-08 2010-04-20 The Research Foundation Of State University Of New York Erogorgiaene congeners and methods and intermediates useful in the preparation of same
CN101400652A (zh) * 2006-03-10 2009-04-01 纽约州州立大学研究基金会 四氢吡啶在治疗中枢神经系统障碍中的应用

Also Published As

Publication number Publication date
EP3226865A4 (en) 2018-06-06
EP3226865A1 (en) 2017-10-11
JP2019070036A (ja) 2019-05-09
AU2015355612B2 (en) 2019-10-03
US20170355676A1 (en) 2017-12-14
WO2016089304A1 (en) 2016-06-09
JP6493711B2 (ja) 2019-04-03
AU2019284008A1 (en) 2020-01-23
JP2017537113A (ja) 2017-12-14
US20180141907A1 (en) 2018-05-24
SG11201701618SA (en) 2017-03-30
AU2015355612A2 (en) 2019-01-31
US10414728B2 (en) 2019-09-17
AU2015355612A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL265590B (en) Formulations and methods for keratin treatment
IL269174A (en) Methods for treating binding-mediated diseases or disorders
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL249580A0 (en) Methods for anesthetizing nerve tissue in the trigeminal nerve pathway and their medical uses
IL250990A0 (en) Materials for human care
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
IL246855A0 (en) Materials for use in the treatment of retinitis
GB201418809D0 (en) Therapeutic agents and uses thereof
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
IL250244A0 (en) Prevention and treatment of inflammatory skin diseases
GB201419559D0 (en) Therapeutic compositions and methods